Last Updated: 16 Sep 2024
Executive Summary
Agenus Inc. (AGEN), a clinical-stage immuno-oncology company, is currently trading at $6.26. Despite strong revenue growth, the company faces challenges with profitability and negative margins. Analysts hold a mixed view on the stock, with one Buy rating and four Hold ratings. The stock's technical analysis suggests a potential for a short-term rally, but the long-term outlook remains uncertain.
Company Overview
Agenus discovers and develops immuno-oncology products. It focuses on developing therapies that target the immune system to fight cancer. The company has a diversified pipeline of product candidates in various stages of development.
Fundamental Analysis
Revenue: Agenus reported revenue of $159.63 million in the trailing twelve months (TTM), a 0.071% decrease year-over-year.
Earnings: The company reported a net loss of $111.4 million in the TTM, resulting in a diluted EPS of -$11.14.
Margins: Agenus has negative profit and operating margins, indicating that the company is not yet profitable.
Return on Assets (ROA): The company's ROA is -0.21%, indicating that it is not generating sufficient returns on its assets.
Return on Equity (ROE): Agenus' ROE is -12.79%, indicating that it is not generating sufficient returns for its shareholders.
Technical Analysis
50-Day Moving Average: The stock is currently trading below its 50-day moving average of $7.44.
200-Day Moving Average: The stock is also trading below its 200-day moving average of $11.71.
Relative Strength Index (RSI): The RSI is currently at 39.67, indicating that the stock is in a neutral zone.
Short Term Outlook
The technical analysis suggests that Agenus may experience a short-term rally. The stock has been consolidating below its moving averages and the RSI is approaching oversold levels. A break above the 50-day moving average could trigger a rally towards the 200-day moving average.
Long Term Outlook
The long-term outlook for Agenus is uncertain. The company faces challenges with profitability and its pipeline of product candidates is still in early stages of development. The stock's high beta of 1.357 also indicates that it is more volatile than the broader market.
Analyst Recommendations
Analysts have a mixed view on Agenus. One analyst has a Buy rating, while four analysts have Hold ratings. The average analyst target price is $9.75, which represents a potential upside of 56% from the current price.
